Skip to content

Study · Non-randomized trial · 2006

6 results

An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide.

Damholt B, Golor G, Wierich W, Pedersen P, Ekblom M, Zdravkovic M

Journal of clinical pharmacology1 Jun 2006Cited by 61 (Europe PMC)

PMID16707410 (opens in a new tab)DOI10.1177/0091270006288215 (opens in a new tab)PepBankPUB-16707410
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In healthy subjects, liraglutide plasma AUC adjusted for body weight was equivalent in young and elderly subjects.

    In plain wordsIn healthy people, the liraglutide level in blood was about the same in young and older people.

    Peptide
    Liraglutide
    Outcome
    No significant changeAUC in young versus elderly subjects
    Study

    n: not reported in source

    Comparator
    Young subjects (18 to 45 years)
    Analysis
    Primary
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1.0 mg single dose · subcutaneous · single doseAs given in this study (human).

    Measurements

    Estimated AUC ratio
    0.94 ratio
    elderly vs young

    Source sentences

    Summary
    The area under the liraglutide plasma concentration curve from time 0 to last quantifiable concentration adjusted for body weight (significant covariate; P = .001) was found to be equivalent in young and elderly subjects (primary end point), with an estimated ratio of 0.94 (90% confidence interval, 0.84-1.06; P = .39).
    2 context sentences
    Summary · context
    Eight male and 8 female subjects were recruited from an 18- to 45-year-old group and an over-65-year-old group, respectively.
    Summary · context
    All subjects received a single subcutaneous dose of 1.0 mg liraglutide.
  2. 02HumanNon-randomized trialPharmacokinetics

    In healthy subjects, gender had no significant impact on liraglutide plasma AUC.

    In plain wordsIn healthy people, men and women had about the same liraglutide level in blood.

    Peptide
    Liraglutide
    Outcome
    No significant changeAUC by gender
    Study

    n: not reported in source

    Comparator
    Other gender
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1.0 mg single dose · subcutaneous · single doseAs given in this study (human).

    Measurements

    Estimated ratio
    1.08 ratio
    gender

    Source sentences

    Summary
    No significant impact of gender was observed (P = .38; estimated ratio, 1.08; 90% confidence interval, 0.93-1.26).
    2 context sentences
    Summary · context
    Eight male and 8 female subjects were recruited from an 18- to 45-year-old group and an over-65-year-old group, respectively.
    Summary · context
    All subjects received a single subcutaneous dose of 1.0 mg liraglutide.
  3. 03HumanNon-randomized trialSafety outcome

    In healthy subjects given a single 1.0 mg dose of liraglutide, adverse events were of mild or moderate severity.

    In plain wordsIn healthy people given one liraglutide dose, side effects were mild or moderate.

    Peptide
    Liraglutide
    Outcome
    Not applicableSeverity of adverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    1.0 mg single dose · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Adverse events were of mild or moderate severity.
    2 context sentences
    Summary · context
    Eight male and 8 female subjects were recruited from an 18- to 45-year-old group and an over-65-year-old group, respectively.
    Summary · context
    All subjects received a single subcutaneous dose of 1.0 mg liraglutide.
  4. 04HumanNon-randomized trialSafety outcome

    Headache was among the most frequently reported adverse events after a single dose of liraglutide in healthy subjects.

    In plain wordsHeadache was one of the most common side effects after one liraglutide dose in healthy people.

    Peptide
    Liraglutide
    Outcome
    Not applicableHeadache
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    1.0 mg single dose · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    The most frequently reported events were headache, vomiting, and nausea.
    2 context sentences
    Summary · context
    Eight male and 8 female subjects were recruited from an 18- to 45-year-old group and an over-65-year-old group, respectively.
    Summary · context
    All subjects received a single subcutaneous dose of 1.0 mg liraglutide.
  5. 05HumanNon-randomized trialSafety outcome

    Vomiting was among the most frequently reported adverse events after a single dose of liraglutide in healthy subjects.

    In plain wordsVomiting was one of the most common side effects after one liraglutide dose in healthy people.

    Peptide
    Liraglutide
    Outcome
    Not applicableVomiting
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.0 mg single dose · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    The most frequently reported events were headache, vomiting, and nausea.
    2 context sentences
    Summary · context
    Eight male and 8 female subjects were recruited from an 18- to 45-year-old group and an over-65-year-old group, respectively.
    Summary · context
    All subjects received a single subcutaneous dose of 1.0 mg liraglutide.
  6. 06HumanNon-randomized trialSafety outcome

    Nausea was among the most frequently reported adverse events after a single dose of liraglutide in healthy subjects.

    In plain wordsNausea was one of the most common side effects after one liraglutide dose in healthy people.

    Peptide
    Liraglutide
    Outcome
    Not applicableNausea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.0 mg single dose · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    The most frequently reported events were headache, vomiting, and nausea.
    2 context sentences
    Summary · context
    Eight male and 8 female subjects were recruited from an 18- to 45-year-old group and an over-65-year-old group, respectively.
    Summary · context
    All subjects received a single subcutaneous dose of 1.0 mg liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT01507337

Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers

Novo Nordisk A/Sn = 32Apr 2004 to Jun 2004

Diabetes · Healthy

Trial pageClinicalTrials.govUpdated 24 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.